


# 4  
B7  
6-19-02



PATENT  
Customer No. 22,852  
Attorney Docket No. 07691.0019

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

**Brendan LARDER et al.**

Serial No.: 09/836,477

Filed: April 18, 2001

For: METHODS FOR MEASURING  
THERAPY RESISTANCE

)  
)  
) Group Art Unit: 3736  
)  
) Examiner: Unassigned  
)  
)  
)  
)



RECEIVED

JUN 17 2002

Technology Center 2100

Commissioner for Patents  
Washington, DC 20231

Sir:



**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.


Dated: June 11, 2002

By:


  
Anthony C. Tridico  
Reg. No. 45,958

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	7691.0019	Appln. No.	09/836,477	<b>RECEIVED</b>
Applicant	LARDER et al.			JUN 17 2002
Filing Date	April 18, 2001	Group:	3736	Technology Center 2100



U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate



FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Harrigan et al., "Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting", AIDS, 13, pp. 1863-1871, (1999)
	Hertogs et al., "Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis", AIDS, 13(14), Poster Abstracts OP3.4, p. 11
	Vandamme et al., "Managing Resistance to Anti-HIV Drugs -An important Consideration for Effective Disease Management", DRUGS 1999, 57(3), pp. 337-361, (1999)
	Walter et al., "Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors", Journal of Clinical Virology, 13, pp. 71-80, (1999)
	Wegner et al., "Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel", AIDS, 14, pp. 1009-1015, (2000)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce